News Q&A

Incoming chairman wants public to know about California stem-cell agency's work.

Diseases such as malaria and HIV still present a major challenge to vaccine development, says Gates foundation's departing global-health chief.

Yusuke Nakamura explains the purpose of his fledgling biomedical office.

Drug treatment for HIV infection is effective in preventing its spread, but implementing this fully will require more resources, says leading NIH scientist.

Edzard Ernst, the world's first professor of alternative medicine, is stepping down.

Telomeres may not predict how long we'll live, but they can still revolutionise medicine, says Nobel laureate Elizabeth Blackburn.

Advances in computer modeling still cannot overcome the fundamental complexity of tornado formation.

Laurent Stricker says Japan's nuclear disaster should mark a turning point for the industry.

Ulrike Beisiegel reflects on her first 100 days in charge of the elite University of Göttingen.

Mission scientists discuss what Richard Branson's deep-sea quest hopes to find.

New science chief envisions a neural 'observatory' to determine the part brain cells play in behaviour.

Part of a massive clean-up team, Gennady Laptev recalls his years working to combat Chernobyl's radioactive legacy.

Institution's president aims to boost quality, collaboration and commercialization.

Researchers predicting the finer effects of climate warming on ecology should take care.

Scientists use satellite imagery to document regime's crimes against civilians.

Closed astrobiology centre to be reborn as private company.

For GlaxoSmithKline's research chief Patrick Vallance, drug development unites in-house depth with external breadth.

Global Young Academy co-chair says the organization can help reintegrate western-educated scientists.

Departing Scripps president defends commercial activity after 25 years in the role.

Joe Aldy, former adviser to Barack Obama for energy and environment, assesses the state of US climate legislation.